BioCision Announces Launch of HistoMailer™
Product News Dec 05, 2011
BioCision, LLC has announced the launch of a new product - the HistoMailer - for safely sending tissue blocks for laboratory analysis.
The HistoMailer represents the first in a series of products designed to specifically address the need for safe, reliable transfer of samples between laboratories.
“We immediately recognized the need for a reliable tool to ship paraffin-embedded tissue blocks, which can melt during transport if not packaged correctly,” said Hugh Douglas, BioCision’s Chief Operating Officer.
Douglas continued, “The HistoMailer is a great fit with our expanding product portfolio of integrated solutions for biomedical sample handling from preparation to shipping. In the coming months, we will be introducing additional products to serve the specific tissue processing needs of clinical histology and pathology labs.”
The HistoMailer was originally developed by technicians at Mayo Medical Laboratories, which receives approximately 30,000 specimens per day from hospitals across the country.
According to Mayo Clinic Operations Coordinator Jeff Wills, “The HistoMailer provides end users with a value add when transporting lab specimens. The container is a full-circle tool, from start to finish and provides Mayo with the opportunity to become more green. Mayo’s Department of Laboratory Medicine and Pathology is currently using the technology, along with over one-thousand users across our client base.” Wills is also an inventor of the HistoMailer technology.
“Working with leading academic institutions to develop new tools and products is an important part of BioCision’s overall strategy to best serve biomedical researchers and clinicians,” said BioCision’s CEO Rolf Ehrhardt, MD, PhD.
BioCision specializes in benchtop products that ensure consistency, reproducibility and standardization of laboratory samples, with applications in drug discovery, and basic and clinical research.
Users benefit from high sample reproducibility and consistency - experiment to experiment, lab to lab and research/clinical site to site.
Mayo Clinic and Mr. J. Willis have a financial interest in the technology referenced in this news release.